Vertex Pharmaceuticals Incorporated Stock price
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
411.4 USD | +0.91% | -0.75% | +1.10% |
Financials (USD)
Sales 2024 * | 10.73B | Sales 2025 * | 11.74B | Capitalization | 105B |
---|---|---|---|---|---|
Net income 2024 * | 3.9B | Net income 2025 * | 4.5B | EV / Sales 2024 * | 8.22 x |
Net cash position 2024 * | 17.11B | Net cash position 2025 * | 21.54B | EV / Sales 2025 * | 7.14 x |
P/E ratio 2024 * |
27.1
x | P/E ratio 2025 * |
23.6
x | Employees | 5,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.66% |
Latest transcript on Vertex Pharmaceuticals Incorporated
1 day | +0.91% | ||
1 week | -0.53% | ||
Current month | -2.22% | ||
1 month | -2.56% | ||
3 months | +0.17% | ||
6 months | +17.91% | ||
Current year | +1.10% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 17-01-31 | |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 19-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 17-06-07 |
Jeffrey Leiden
CHM | Chairman | 68 | 09-07-07 |
Bruce Sachs
BRD | Director/Board Member | 64 | 97-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.67% | 0 M€ | 0.00% | - | |
7.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 411.4 | +0.91% | 926,467 |
24-03-15 | 407.7 | -0.26% | 1,905,702 |
24-03-14 | 408.8 | -1.07% | 1,031,358 |
24-03-13 | 413.2 | +0.18% | 764,712 |
24-03-12 | 412.4 | -0.49% | 888,995 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.10% | 105B | |
+9.29% | 104B | |
-3.00% | 22.09B | |
-11.89% | 21.98B | |
-26.59% | 20.17B | |
-5.20% | 19.49B | |
-6.58% | 17.75B | |
+5.83% | 13.84B | |
+7.46% | 11.64B | |
+28.56% | 11.55B |